MSD continues to pursue patent infringement suits in federal court
against companies filing ANDA’s for generic alendronate (Fosamax)
and montelukast (Singulair). AstraZeneca and MSD have filed
patent infringement suits in…
provides in-depth news coverage of intellectual property lawsuits involving public companies with assets of USD $1 billion or more. Coverage focuses on the infringement of intellectual property rights (including patents, copyrights, trademarks, trade dress, trade secrets, and royalties) and corporate indemnification of intellectual property violations.